Asunto(s)
Várices Esofágicas y Gástricas , Hemorragia Gastrointestinal , Cirrosis Hepática , Lipresina , Terlipresina , Vasoconstrictores , Humanos , Terlipresina/administración & dosificación , Terlipresina/uso terapéutico , Cirrosis Hepática/complicaciones , Cirrosis Hepática/tratamiento farmacológico , Várices Esofágicas y Gástricas/tratamiento farmacológico , Hemorragia Gastrointestinal/tratamiento farmacológico , Hemorragia Gastrointestinal/etiología , Vasoconstrictores/administración & dosificación , Lipresina/análogos & derivados , Lipresina/administración & dosificación , Lipresina/uso terapéutico , Administración IntravenosaAsunto(s)
Cirrosis Hepática , Terlipresina , Vasoconstrictores , Humanos , Terlipresina/uso terapéutico , Cirrosis Hepática/tratamiento farmacológico , Cirrosis Hepática/complicaciones , Vasoconstrictores/efectos adversos , Vasoconstrictores/uso terapéutico , Lipresina/análogos & derivados , Lipresina/uso terapéutico , Lipresina/efectos adversosAsunto(s)
Várices Esofágicas y Gástricas , Hemorragia Gastrointestinal , Cirrosis Hepática , Lipresina , Terlipresina , Vasoconstrictores , Humanos , Terlipresina/administración & dosificación , Terlipresina/uso terapéutico , Cirrosis Hepática/complicaciones , Cirrosis Hepática/tratamiento farmacológico , Várices Esofágicas y Gástricas/tratamiento farmacológico , Hemorragia Gastrointestinal/tratamiento farmacológico , Hemorragia Gastrointestinal/etiología , Vasoconstrictores/administración & dosificación , Lipresina/análogos & derivados , Lipresina/administración & dosificación , Lipresina/uso terapéutico , Administración IntravenosaRESUMEN
Hepatorenal syndrome (HRS) is a feared complication in patients with advanced cirrhosis and is associated with significant morbidity and mortality. While recognized as a distinct physiologic condition for well over one hundred years, a lack of objective diagnostic tests has made the diagnosis one of exclusion. Since 1979, multiple sets of diagnostic criteria have been proposed. Though varying in detail, the principal intent of these criteria is to identify patients with severe, functional acute kidney injury that is unresponsive to volume resuscitation and exclude those with structural injury. However, accurate differential diagnosis remains challenging. Recently, multiple urinary biomarkers of kidney injury, including neutrophil gelatinase-associated lipocalin, have been studied as a means of objectively phenotyping etiologies of acute kidney injury in patients with cirrhosis. Along with markers reflecting tubular functional integrity, including the fractional excretion of sodium, injury markers will likely be incorporated into future diagnostic criteria. Making an accurate diagnosis is critical, as therapeutic options exist for HRS but must be given in a timely manner and only to those patients likely to benefit. Terlipressin, an analog of vasopressin, is the first line of therapy for HRS in much of the world and has recently been approved for use in the United States. Significant questions remain regarding the optimal dosing strategy, metrics for titration, and the potential role of point-of-care ultrasound to help guide concurrent albumin administration.
Asunto(s)
Biomarcadores , Síndrome Hepatorrenal , Terlipresina , Humanos , Síndrome Hepatorrenal/diagnóstico , Síndrome Hepatorrenal/terapia , Síndrome Hepatorrenal/etiología , Biomarcadores/orina , Terlipresina/uso terapéutico , Lipresina/análogos & derivados , Lipresina/uso terapéutico , Vasoconstrictores/uso terapéutico , Diagnóstico Diferencial , Lipocalina 2/orina , Lesión Renal Aguda/diagnóstico , Lesión Renal Aguda/terapiaAsunto(s)
Lesión Renal Aguda , Síndrome Hepatorrenal , Lipresina , Terlipresina , Vasoconstrictores , Humanos , Terlipresina/uso terapéutico , Síndrome Hepatorrenal/tratamiento farmacológico , Lesión Renal Aguda/diagnóstico , Lipresina/análogos & derivados , Lipresina/uso terapéutico , Lipresina/efectos adversos , Vasoconstrictores/uso terapéutico , Vasoconstrictores/efectos adversosAsunto(s)
Lesión Renal Aguda , Síndrome Hepatorrenal , Terlipresina , Vasoconstrictores , Humanos , Terlipresina/uso terapéutico , Síndrome Hepatorrenal/tratamiento farmacológico , Lesión Renal Aguda/diagnóstico , Lesión Renal Aguda/inducido químicamente , Vasoconstrictores/uso terapéutico , Vasoconstrictores/efectos adversos , Lipresina/análogos & derivados , Lipresina/efectos adversos , Lipresina/uso terapéuticoAsunto(s)
Lesión Renal Aguda , Síndrome Hepatorrenal , Terlipresina , Vasoconstrictores , Terlipresina/uso terapéutico , Humanos , Síndrome Hepatorrenal/tratamiento farmacológico , Lesión Renal Aguda/tratamiento farmacológico , Vasoconstrictores/uso terapéutico , Vasoconstrictores/efectos adversos , Lipresina/análogos & derivados , Lipresina/uso terapéuticoAsunto(s)
Lesión Renal Aguda , Síndrome Hepatorrenal , Terlipresina , Vasoconstrictores , Terlipresina/uso terapéutico , Humanos , Síndrome Hepatorrenal/tratamiento farmacológico , Lesión Renal Aguda/tratamiento farmacológico , Vasoconstrictores/uso terapéutico , Vasoconstrictores/efectos adversos , Lipresina/análogos & derivados , Lipresina/uso terapéuticoAsunto(s)
Lesión Renal Aguda , Síndrome Hepatorrenal , Terlipresina , Vasoconstrictores , Terlipresina/uso terapéutico , Humanos , Síndrome Hepatorrenal/tratamiento farmacológico , Lesión Renal Aguda/tratamiento farmacológico , Vasoconstrictores/uso terapéutico , Vasoconstrictores/efectos adversos , Lipresina/análogos & derivados , Lipresina/uso terapéutico , Lipresina/efectos adversosRESUMEN
INTRODUCTION AND OBJECTIVES: Hepatorenal syndrome (HRS) is a serious complication of cirrhosis treated with various medications. We aim to evaluate terlipressin and albumin's effectiveness and safety compared to albumin and noradrenaline in adult hepatorenal disease patients. MATERIALS AND METHODS: Clinical trials from four databases were included. Cochrane's approach for calculating bias risk was utilized. We rated the quality evaluation by Grading of Recommendations Assessment, Development, and Evaluation (GRADE). We included the following outcomes: serum creatinine (mg/dl), urine output (ml/24 h), mean arterial pressure (mmHg), reversal rate of HRS, mortality rate, blood plasma renin activity (ng/ml/h), plasma aldosterone concentration (pg/ml), urine sodium (mEq/l), and creatinine clearance (ml/min). RESULTS: Our analysis of nine clinical studies revealed that the noradrenaline group was associated with higher creatinine clearance (MD = 4.22 [0.40, 8.05]), (P = 0.03). There were no significant differences in serum creatinine levels (MD = 0.03 [-0.07, 0.13]), urinary sodium (MD = -1.02 [-5.15, 3.11]), urine output (MD = 32.75 [-93.94, 159.44]), mean arterial pressure (MD = 1.40 [-1.17, 3.96]), plasma renin activity (MD = 1.35 [-0.17, 2.87]), plasma aldosterone concentration (MD = 55.35 [-24.59, 135.29]), reversal rate of HRS (RR = 1.15 [0.96, 1.37]), or mortality rate (RR = 0.87 [0.74, 1.01]) between the two groups (p-values > 0.05). CONCLUSIONS: Noradrenaline is a safe alternative medical therapy for HRS.
Asunto(s)
Albúminas , Síndrome Hepatorrenal , Norepinefrina , Terlipresina , Vasoconstrictores , Humanos , Terlipresina/uso terapéutico , Síndrome Hepatorrenal/tratamiento farmacológico , Norepinefrina/uso terapéutico , Norepinefrina/orina , Norepinefrina/sangre , Albúminas/uso terapéutico , Resultado del Tratamiento , Vasoconstrictores/uso terapéutico , Vasoconstrictores/efectos adversos , Adulto , Creatinina/sangre , Lipresina/análogos & derivados , Lipresina/uso terapéutico , Lipresina/efectos adversosRESUMEN
BACKGROUND & AIMS: The management of acute kidney injury (AKI) in cirrhosis is challenging. The EASL guidelines proposed an algorithm for the management of AKI, but this has never been validated. We aimed to prospectively evaluate this algorithm in clinical practice. METHODS: We performed a prospective cohort study in consecutive hospitalized patients with cirrhosis and AKI. The EASL management algorithm includes identification/treatment of precipitating factors, 2-day albumin infusion in patients with AKI ≥stage 1B, and treatment with terlipressin in patients with hepatorenal syndrome (HRS-AKI). The primary outcome was treatment response, which included both full and partial response. Secondary outcomes were survival and adverse events associated with terlipressin therapy. RESULTS: A total of 202 AKI episodes in 139 patients were included. Overall treatment response was 80%, while renal replacement therapy was required in only 8%. Response to albumin infusion was achieved in one-third of episodes. Of patients not responding to albumin, most (74%) did not meet the diagnostic criteria of HRS-AKI, with acute tubular necrosis (ATN) being the most common phenotype. The response rate in patients not meeting the criteria for HRS-AKI was 70%. Only 30 patients met the diagnostic criteria for HRS-AKI, and their response rate to terlipressin was 61%. Median time from AKI diagnosis to terlipressin initiation was only 2.5 days. While uNGAL (urinary neutrophil gelatinase-associated lipocalin) could differentiate ATN from other phenotypes (AUROC 0.78), it did not predict response to therapy in HRS-AKI. Ninety-day transplant-free survival was negatively associated with MELD-Na, ATN and HRS-AKI as well as uNGAL. Three patients treated with terlipressin developed pulmonary edema. CONCLUSIONS: The application of the EASL AKI algorithm is associated with very good response rates and does not significantly delay initiation of terlipressin therapy. IMPACT AND IMPLICATIONS: The occurrence of acute kidney injury (AKI) in patients with cirrhosis is associated with poor short-term mortality. Improving its rapid identification and prompt management was the focus of the recently proposed EASL AKI algorithm. This is the first prospective study demonstrating that high AKI response rates are achieved with the use of this algorithm, which includes identification of AKI, treatment of precipitating factors, a 2-day albumin challenge in patients with AKI ≥1B, and supportive therapy in patients with persistent AKI not meeting HRS-AKI criteria or terlipressin with albumin in those with HRS-AKI. These findings support the use of this algorithm in clinical practice.
Asunto(s)
Lesión Renal Aguda , Algoritmos , Cirrosis Hepática , Terlipresina , Humanos , Lesión Renal Aguda/etiología , Lesión Renal Aguda/diagnóstico , Masculino , Femenino , Estudios Prospectivos , Persona de Mediana Edad , Cirrosis Hepática/complicaciones , Terlipresina/administración & dosificación , Anciano , Albúminas/administración & dosificación , Vasoconstrictores/administración & dosificación , Vasoconstrictores/uso terapéutico , Lipresina/análogos & derivados , Lipresina/administración & dosificación , Lipresina/uso terapéutico , Resultado del Tratamiento , Síndrome Hepatorrenal/etiología , Síndrome Hepatorrenal/diagnóstico , Síndrome Hepatorrenal/tratamiento farmacológico , Guías de Práctica Clínica como AsuntoRESUMEN
Variceal bleeding is a major complication and the leading cause of death in patients with cirrhosis and portal hypertension. This study aims to compare the efficacy and safety of terlipressin vs octreotide as an adjuvant to endoscopic management of patients with esophageal variceal bleeding in a real-time scenario. We reviewed the medical records of patients with esophageal variceal bleeding from January 2005 to December 2020 at our tertiary care Aga Khan University Hospital. Mortality was assessed after 6 weeks. A total of 842 patients with variceal bleed were evaluated. 624 patients (74.1%) and 218 patients (25.9%) received Terlipressin and Octreotide respectively. On multiple regression analysis, cardiac events during hospital stay (OR: 11.22), presence of Porto-systemic encephalopathy (OR: 3.79), and elevated bilirubin levels at the time of presentation were found to be independent risk factors for increased six weeks mortality. Moreover, cardiac events during hospital stay (OR: 3.26), Porto-systemic encephalopathy at presentation (OR: 3.06), and octreotide administration (OR: 1.80) were identified as independent risk factors for increased length of hospital stay. Terlipressin and Octreotide have similar outcomes in terms of control of bleeding, hospital stay, mortality, and side effects when used as adjuvant therapy for the management of variceal bleeding.
Asunto(s)
Encefalopatías , Várices Esofágicas y Gástricas , Várices , Humanos , Terlipresina/uso terapéutico , Octreótido/efectos adversos , Hemorragia Gastrointestinal/tratamiento farmacológico , Hemorragia Gastrointestinal/etiología , Vasoconstrictores/efectos adversos , Lipresina/uso terapéutico , Várices Esofágicas y Gástricas/complicaciones , Várices Esofágicas y Gástricas/tratamiento farmacológico , Várices/complicaciones , Cirrosis Hepática/complicaciones , Cirrosis Hepática/tratamiento farmacológico , Encefalopatías/tratamiento farmacológicoAsunto(s)
Terlipresina , Humanos , Terlipresina/administración & dosificación , Gabapentina/administración & dosificación , Gabapentina/uso terapéutico , Vasoconstrictores/administración & dosificación , Vasoconstrictores/efectos adversos , Lipresina/análogos & derivados , Lipresina/administración & dosificación , Lipresina/efectos adversos , MasculinoRESUMEN
PURPOSE OF REVIEW: The definition and diagnostic criteria of hepatorenal syndrome-acute kidney injury (HRS-AKI) has undergone recent changes. A major vasoconstrictor, terlipressin, has recently been approved as pharmacotherapy for HRS-AKI in the United States. The purpose of this review is to familiarize the readers with these new diagnostic criteria of HRS-AKI, and how best to use terlipressin. RECENT FINDINGS: Terlipressin is effective either as bolus dosing or continuous infusion and can achieve reversal of HRS-AKI in approximately 40% of patients. Continuous infusion allows lower daily dose with equal efficacy and less side effects but not an approved mode of administration in the United States. Response to terlipressin in the randomized controlled trials was defined as repeat reduction of serum creatinine to less than 1.5âmg/dl. Newer studies will likely require response to treatment to be defined as a repeat serum creatinine to be less than 0.3âmg/dl from baseline. Terlipressin use is associated with ischemic side effects and potential for respiratory failure development. SUMMARY: Careful patient selection and close monitoring are necessary for its use. Response to terlipressin with HRS-AKI reversal is associated with improved outcomes with better survival and less requirement for renal replacement therapy.
Asunto(s)
Lesión Renal Aguda , Síndrome Hepatorrenal , Humanos , Terlipresina/uso terapéutico , Lipresina/uso terapéutico , Lipresina/efectos adversos , Síndrome Hepatorrenal/tratamiento farmacológico , Creatinina/uso terapéutico , Resultado del Tratamiento , Vasoconstrictores/uso terapéutico , Vasoconstrictores/efectos adversos , Lesión Renal Aguda/tratamiento farmacológico , Lesión Renal Aguda/inducido químicamenteRESUMEN
We present the case of a woman in her 60s with Child-Pugh C cirrhosis who developed pericardial tamponade during an admission for a haemothorax secondary to a mechanical fall. The patient developed haemodynamic compromise with a rapid decline in renal function. During an open subxiphoid drain tube insertion, a pre-existing peritoneopericardial communication was noted, with ascites in the peritoneal cavity on view. The serum ascites albumin gradient was 14 g/L. Maximal medical therapy was commenced including diuresis and albumin, with adjunctive terlipressin infusion which restored her baseline renal function and resolved the effusion. We believe this is the first case report of using open drainage, maximal medical therapy and terlipressin to successfully treat hepatic hydropericardium and its subsequent renal compromise.
Asunto(s)
Ascitis , Derrame Pericárdico , Femenino , Humanos , Terlipresina/uso terapéutico , Ascitis/tratamiento farmacológico , Ascitis/etiología , Riñón , Cirrosis Hepática/complicaciones , Derrame Pericárdico/complicaciones , Edema/complicaciones , Albúminas , Drenaje/efectos adversos , Lipresina/uso terapéuticoRESUMEN
The treatment of choice for hepatorenal syndrome-acute kidney injury (HRS-AKI) is vasoconstrictor therapy in combination with albumin, preferably norepinephrine or terlipressin as recommended by recent guidelines. In the absence of larger head-to-head trials comparing the efficacy of terlipressin and norepinephrine, meta-analysis of smaller studies can provide insights needed to understand the comparative effects of these medications. Additionally, recent changes in the HRS diagnosis and treatment guidelines underscore the need for newer analyses comparing terlipressin and norepinephrine. In this systematic review, we aimed to assess reversal of hepatorenal syndrome (HRS) and 1-month mortality in subjects receiving terlipressin or norepinephrine for the management of HRS-AKI. We searched literature databases, including PubMed, Cochrane, Clinicaltrials.gov, International Clinical Trials Registry Platform, Embase, and ResearchGate, for randomized controlled trials (RCTs) published from January 2007 to June 2023 on June 26, 2023. Only trials comparing norepinephrine and albumin with terlipressin and albumin for the treatment of HRS-AKI in adults were included, and trials without HRS reversal as an endpoint or nonresponders were excluded. Pairwise meta-analyses with the random effects model were conducted to estimate odds ratios (ORs) for HRS reversal and 1-month mortality as primary outcomes. Additional outcomes assessed, included HRS recurrence, predictors of response, and incidence of adverse events (AEs). We used the Cochrane risk of bias assessment tool for quality assessment. We included 7 RCTs with a total of 376 subjects with HRS-AKI or HRS type 1. This meta-analysis showed numerically higher rates of HRS reversal (OR 1.33, 95% confidence interval [CI] [0.80-2.22]; P = 0.22) and short-term survival (OR 1.50, 95% CI [0.64-3.53]; P = 0.26) with terlipressin, though these results did not reach statistical significance. Terlipressin was associated with AEs such as abdominal pain and diarrhea, whereas norepinephrine was associated with cardiovascular AEs such as chest pain and ischemia. Most of the AEs were reversible with a reduction in dose or discontinuation of therapy across both arms. Of the terlipressin-treated subjects, 5.3% discontinued therapy due to serious AEs compared to 2.7% of the norepinephrine-treated subjects. Limitations of this analysis included small sample size and study differences in HRS-AKI diagnostic criteria. As more studies using the new HRS-AKI criteria comparing terlipressin and norepinephrine are completed, a clearer understanding of the comparability of these 2 therapies will emerge.
Asunto(s)
Lesión Renal Aguda , Síndrome Hepatorrenal , Adulto , Humanos , Terlipresina/uso terapéutico , Norepinefrina/efectos adversos , Síndrome Hepatorrenal/tratamiento farmacológico , Lipresina/efectos adversos , Resultado del Tratamiento , Vasoconstrictores/efectos adversos , Lesión Renal Aguda/inducido químicamente , Albúminas/efectos adversosRESUMEN
Hepatorenal syndrome-acute kidney injury (HRS-AKI), a serious complication of decompensated cirrhosis, has limited therapeutic options and significant morbidity and mortality. Terlipressin improves renal function in some patients with HRS-1, while liver transplantation (LT) is a curative treatment for advanced chronic liver disease. Renal failure post-LT requiring renal replacement therapy (RRT) is a major risk factor for graft and patient survival. A post hoc analysis with a 12-month follow-up of LT recipients from a placebo-controlled trial of terlipressin (CONFIRM; NCT02770716) was conducted to evaluate the need for RRT and overall survival. Patients with HRS-1 were treated with terlipressin plus albumin or placebo plus albumin for up to 14 days. RRT was defined as any type of procedure that replaced kidney function. Outcomes compared between groups included the incidence of HRS-1 reversal, the need for RRT (pretransplant and posttransplant), and overall survival. Of the 300 patients in CONFIRM (terlipressin n = 199; placebo, n = 101), 70 (23%) underwent LT alone (terlipressin, n = 43; placebo, n = 27) and 5 had simultaneous liver-kidney transplant (terlipressin, n = 3, placebo, n = 2). The rate of HRS reversal was significantly higher in the terlipressin group compared with the placebo group (37%, n = 16 vs. 15%, n = 4; p = 0.033). The pretransplant need for RRT was significantly lower among those who received terlipressin ( p = 0.007). The posttransplant need for RRT, at 12 months, was significantly lower among those patients who received terlipressin and were alive at Day 365, compared to placebo ( p = 0.009). Pretransplant treatment with terlipressin plus albumin in patients with HRS-1 decreased the need for RRT pretransplant and posttransplant.
Asunto(s)
Síndrome Hepatorrenal , Trasplante de Hígado , Humanos , Terlipresina/efectos adversos , Síndrome Hepatorrenal/etiología , Síndrome Hepatorrenal/terapia , Vasoconstrictores/uso terapéutico , Trasplante de Hígado/efectos adversos , Terapia de Reemplazo Renal/efectos adversos , Albúminas/efectos adversos , Lipresina/efectos adversos , Resultado del Tratamiento , Cirrosis Hepática/complicacionesRESUMEN
BACKGROUND AND AIMS: Treatment of hepatorenal syndrome-acute kidney injury (HRS-AKI), with terlipressin and albumin, provides survival benefits, but may be associated with cardiopulmonary complications. We analyzed the predictors of terlipressin response and mortality using point-of-care echocardiography (POC-Echo) and cardiac and renal biomarkers. APPROACH: Between December 2021 and January 2023, patients with HRS-AKI were assessed with POC-Echo and lung ultrasound within 6 hours of admission, at the time of starting terlipressin (48 h), and at 72 hours. Volume expansion was done with 20% albumin, followed by terlipressin infusion. Clinical data, POC-Echo data, and serum biomarkers were prospectively collected. Cirrhotic cardiomyopathy (CCM) was defined per 2020 criteria. RESULTS: One hundred and forty patients were enrolled (84% men, 59% alcohol-associated disease, mean MELD-Na 25±SD 5.6). A median daily dose of infused terlipressin was 4.3 (interquartile range: 3.9-4.6) mg/day; mean duration 6.4 ± SD 1.9 days; the complete response was in 62% and partial response in 11%. Overall mortality was 14% and 16% at 30 and 90 days, respectively. Cutoffs for prediction of terlipressin nonresponse were cardiac variables [ratio of early mitral inflow velocity and mitral annular early diastolic tissue doppler velocity > 12.5 (indicating increased left filling pressures, C-statistic: 0.774), tissue doppler mitral velocity < 7 cm/s (indicating impaired relaxation; C-statistic: 0.791), > 20.5% reduction in cardiac index at 72 hours (C-statistic: 0.885); p < 0.001] and pretreatment biomarkers (CysC > 2.2 mg/l, C-statistic: 0.640 and N-terminal proBNP > 350 pg/mL, C-statistic: 0.655; p <0.050). About 6% of all patients with HRS-AKI and 26% of patients with CCM had pulmonary edema. The presence of CCM (adjusted HR 1.9; CI: 1.8-4.5, p = 0.009) and terlipressin nonresponse (adjusted HR 5.2; CI: 2.2-12.2, p <0.001) were predictors of mortality independent of age, sex, obesity, DM-2, etiology, and baseline creatinine. CONCLUSIONS: CCM and reduction in cardiac index, reliably predict terlipressin nonresponse. CCM is independently associated with poor survival in HRS-AKI.